Takia Oglesby, MD
Interventional Pain Medicine · Columbus, GANPI 1972720928
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,278 of the $8,019 with a category attached, or 78.3%. 29 manufacturers reported payments, led by Boston Scientific at 57.3% of the total. 2025 is the largest year on record at $2,993, more than ten times the $89 reported in 2019.
Across 202 payments — averaging $39.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$5K
- Medtronic$631
- Curonix LLC$351
- IBSA Pharma Inc.$299
- Forte Bio-pharma LLC$299
- Siemens Medical Solutions USA, Inc.$204
- plus $2K from 23 others
What the payments were for
- Travel & lodging$1,69921%
- Food & beverage$6,27878%
- Education$421%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 77 | $4,597 |
| Medtronic(2 entities) | 10 | $631 |
| Curonix LLC | 5 | $351 |
| IBSA Pharma Inc. | 19 | $299 |
| Forte Bio-pharma LLC | 8 | $299 |
| Siemens Medical Solutions USA, Inc. | 5 | $204 |
| Collegium Pharmaceutical, Inc. | 11 | $188 |
| Nalu Medical, Inc. | 3 | $184 |
| AbbVie(2 entities) | 10 | $158 |
| Nevro Corp. | 2 | $158 |
| Almatica Pharma LLC | 7 | $138 |
| GRT US Holding, Inc. | 7 | $110 |
| Amgen(2 entities) | 5 | $91 |
| Abbott | 5 | $90 |
| Biohaven Pharmaceuticals, Inc. | 4 | $69 |
| Si-bone, Inc. | 2 | $69 |
| Arbor Pharmaceuticals, Inc. | 4 | $69 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $46 |
| Redhill Biopharma Inc. | 2 | $41 |
| Spinal Simplicity, LLC | 1 | $39 |
| Scilex Pharmaceuticals Inc. | 2 | $37 |
| Pfizer | 2 | $36 |
| Zyla Life Sciences, Inc. | 2 | $26 |
| SPR Therapeutics, Inc | 1 | $21 |
| Vertos Medical, Inc. | 1 | $18 |
| Biotronik NRO, Inc. | 1 | $15 |
| MDD US Operations, LLC | 1 | $12 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| Daiichi Sankyo Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,019 in reported general payments places this provider in the 65th percentile of 129 interventional pain medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 249 | $114,133 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 1,654 | $84,319 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,099 | $26,655 |
| GraliseGabapentin | 22 | $25,931 |
| Hysingla ErHydrocodone Bitartrate | 50 | $22,376 |
| Diclofenac Sodium | 69 | $20,621 |
| Pregabalin | 812 | $18,962 |
| MovantikNaloxegol Oxalate | 40 | $17,139 |
| Fentanyl | 189 | $16,368 |
| SavellaMilnacipran Hcl | 26 | $16,158 |
| Gabapentin ErGabapentin | 29 | $13,065 |
| Celecoxib | 921 | $12,126 |
| Diflorasone Diacetate | 14 | $11,659 |
| Oxycodone Hcl | 460 | $7,801 |
| ZtlidoLidocaine | 16 | $6,408 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $188 | $114,133249 claims |
| Almatica Pharma LLCGralise | $138 | $25,93122 claims |
| Redhill Biopharma Inc.Movantik | $41 | $17,13940 claims |
| AbbVieSavella | $158 | $16,15826 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $37 | $6,40816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 129 interventional pain medicine providers in Georgia.
Other interventional pain medicine in Columbus
- Kenneth BarngroverColumbus$12K
- Emmanuel GageBrunswick$602K
- Jordan TateJasper$540K
- Christopher BovinetBrunswick$338K
- David RosenfeldCovington$249K
- Nathan NeufeldNewnan$171K
- Ryan BudwanyLawrenceville$123K
- Alexandra MoreiraAtlanta$79K
- Sushanth BodaNewnan$55K
- Christopher AndrianoStockbridge$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.